^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    DRP®-Dovitinib

    Company:
    Allarity Therap
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    The DRP platform, an algorithm-based tool that Allarity has developed specifically to repurpose the once-failed dovitinib, uses gene expression and microarray data to identify potential responders based on mRNA from biopsied tumor samples, and is rooted in cell line data.
    Cancer:
    Breast Cancer, Endometrial Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Cancer, Renal Cell Carcinoma
    Drug:
    dovitinib (TKI258)
    Confirmatory trial(s)
    LiPlaCis
    ,
    NCT01861496
    |
    J Clin Oncol